Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

References

• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Santagostino E, Auerswald G, Benson G, et al. Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol. 2015;94(4):284–289. doi:10.1111/ejh.12433
   PubMed Web of Science ®Google Scholar
• Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood. 2012;120(4):720–727. doi:10.1182/blood-2012-03-378927
   PubMed Web of Science ®Google Scholar
• Kogenate-w-vial-adapter prescribing information. Bayer; 2019.
   Google Scholar
• Kovaltry. prescribing information. Bayer; 2016.
   Google Scholar
• Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93(3):457–467. doi:10.1160/TH03-10-0643
   PubMed Web of Science ®Google Scholar
• Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost. 2010;8(1):83–89. doi:10.1111/j.1538-7836.2009.03650.x
   PubMed Web of Science ®Google Scholar
• Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. Thromb Haemost. 2000;83(6):811–816. doi:10.1055/s-0037-1613925
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11(6):1119–1127. doi:10.1111/jth.12202
   PubMed Web of Science ®Google Scholar
• Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360–369. doi:10.1111/jth.12828
   PubMed Web of Science ®Google Scholar
• Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22(5):706–712. doi:10.1111/hae.12952
   PubMed Web of Science ®Google Scholar
• Ljung R, Kenet G, Mancuso ME, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids trial. Haemophilia. 2016;22(3):354–360. doi:10.1111/hae.12866
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Windyga J, Hampton K, et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia. 2016;22(3):349–353. doi:10.1111/hae.12839
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Lopez Fernandez MF, Santagostino E, et al. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years. Eur J Haematol. 2020;104(6):594–601. doi:10.1111/ejh.13402
   PubMed Web of Science ®Google Scholar
• Shah A, Delesen H, Garger S, Lalezari S. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia. 2015;21(6):766–771. doi:10.1111/hae.12691
   PubMed Web of Science ®Google Scholar
• Ishaque A, Thrift J, Murphy JE, Konstantinov K. Over-expression of Hsp70 in BHK-21 cells engineered to produce recombinant factor VIII promotes resistance to apoptosis and enhances secretion. Biotechnol Bioeng. 2007;97(1):144–155. doi:10.1002/bit.21201
   PubMed Web of Science ®Google Scholar
• Garger S, Severs J, Regan L, et al. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics. Haemophilia. 2017;23(2):e67–e78. doi:10.1111/hae.13148
   PubMed Web of Science ®Google Scholar
• Shah A, Solms A, Garmann D, et al. Improved pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A. Clin Pharmacokinet. 2017;56(9):1045–1055. doi:10.1007/s40262-016-0492-2
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Presley RJ, Lusher JM, et al. Complications of haemophilia in babies (first two years of life): a report from the centers for disease control and prevention universal data collection system. Haemophilia. 2017;23(2):207–214. doi:10.1111/hae.13081
   PubMed Web of Science ®Google Scholar
• Bradshaw CJ, Bandi AS, Muktar Z, et al. International study of the epidemiology of paediatric trauma: PAPSA research study. World J Surg. 2018;42(6):1885–1894. doi:10.1007/s00268-017-4396-6
   PubMed Web of Science ®Google Scholar
• Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol. 2020;191(2):282–290. doi:10.1111/bjh.16964
   PubMed Web of Science ®Google Scholar
• Chaudhary S, Figueroa J, Shaikh S, et al. Pediatric falls ages 0–4: understanding demographics, mechanisms, and injury severities. Inj Epidemiol. 2018;5(Suppl 1):7. doi:10.1186/s40621-018-0147-x
   PubMedGoogle Scholar
• Mancuso ME, Oldenburg J, Boggio L, et al. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: evidence from clinical trials and real-world practice. Haemophilia. 2020;26(4):637–642. doi:10.1111/hae.14018
   PubMed Web of Science ®Google Scholar
• Santoro C, Fuh B, Le PQ, et al. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): final results of the global real-world study, Taurus. Eur J Haematol. 2023;110(1):77–87. doi:10.1111/ejh.13876
   PubMed Web of Science ®Google Scholar